ClinicalTrials.gg
CompletedNCT04471428CONTACT-01Updated Dec 22, 2025Results posted

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

A Phase 3 interventional study of Cabozantinib and Atezolizumab in Carcinoma, Non-Small-Cell Lung, sponsored by Hoffmann-La Roche. Completed at 92 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 6 under way, none of them phase 3. cabozantinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
3rd of 16
366 · median 39
Started
2020
with 1 other
Phase 3
Only one
of the 16
Registered
13th of 16
by date
Lead sponsor
1 of 16
Hoffmann-La Roche

Among the 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 2 that started in 2020, is the only one in phase 3, and was the 13th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients with metastatic NSCLC, with no sensitizing EGFR mutation or ALK translocation, who have progressed following treatment with platinum-containing chemotherapy and anti-PD-L1/PD-1 antibody, administered concurrently or sequentially.

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed NSCLC
  • Documented radiographic disease progression during or following treatment with platinum-containing chemotherapy and /PD-1 antibody, administered concurrently or sequentially for metastatic NSCLC
  • per v1.1 outside CNS as assessed by investigator
  • Known PD-L1 status or availability of tumor tissue for central PD-L1 testing
  • Performance Status score of 0 or 1
  • Recovery to baseline or Grade \<=1 v5.0 from toxicities related to any prior treatments, unless adverse events are clinically nonsignificant and/or stable on supportive therapy in the opinion of the investigator
  • Adequate hematologic and end-organ function
  • Negative test at screening
  • Negative surface antigen (HBsAg) test at screening
  • Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening
  • Negative virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use , and agreement to refrain from donating eggs,
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with the following agents for NSCLC: Cabozantinib, Docetaxel, Combination of an /PD-1 antibody concurrently with a vascular endothelial growth factor (VEGF)R targeting tyrosine kinase inhibitor (TKI)
  • Treatment with therapy within 28 days prior to initiation of study treatment
  • Documentation of known sensitizing mutation in the EGFR gene or ALK fusion oncogene
  • Patients with known ROS1 rearrangements, BRAF V600E mutations, or other actionable oncogenes with approved therapies if available
  • Symptomatic, untreated, or actively progressing
  • History of
  • Uncontrolled tumor-related pain
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (more frequently than once monthly)
  • Severe hepatic impairment
  • Uncontrolled or symptomatic hypercalcemia
  • Any other active at the time of initiation of study treatment or diagnosis of another malignancy within 3 years prior to initiation of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, incidental prostate cancer, or carcinoma in situ of the prostate, cervix, or breast
  • Stroke, , myocardial infarction or other symptomatic ischemic events within 6 months of initiation of study treatment
  • Significant vascular disease within 6 months of initiation of study treatment
  • Significant cardiovascular disease within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina
  • Active tuberculosis
  • Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that, in the opinion on the investigator, could impact patient safety
  • Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
  • Current treatment with anti-viral therapy for
  • Major surgical procedure, other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
  • Pregnant or lactating females, or intention of becoming pregnant during the treatment with atezolizumab in combination with cabozantinib in the experimental arm or during the treatment with docetaxel in the control arm, or within 5 months after the final dose of atezolizumab and/or 4 months after the final dose of cabozantinib, whichever is later.
  • Ongoing Grade >= 2 sensory or motor neuropathy
  • Active or history of disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, granulomatosis with polyangiitis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis with the following exceptions: Patients with a history of autoimmune-mediated hypothyroidism who are on thyroid replacement hormone are eligible for the study. Patients with controlled Type 1 diabetes mellitus are eligible for the study. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only are eligible for the study provided all of following conditions are met: Rash must cover \< 10% of body surface area.
  • Pharmacologically uncompensated, symptomatic hypothyroidism
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Prior allogeneic stem cell or solid organ transplantation
  • Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
  • Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment
  • Treatment with systemic medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions: Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication are eligible for the study after Medical Monitor confirmation has been obtained. Patients who received mineralocorticoids, inhaled or low-dose systemic for or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.
  • History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  • Known to Chinese hamster ovary cell products or to any component of the atezolizumab formulation
  • Known allergy or hypersensitivity to any component of the cabozantinib formulation
  • History of severe hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80
  • Concomitant anticoagulation with coumarin agents, direct thrombin inhibitor dabigatran, direct factor Xa inhibitor betrixaban, or inhibitors
  • History of risk factors for torsades de pointes
  • interval corrected through use of Fridericia's formula (QTcF) > 480 ms per within 14 days before initiation of study treatment
  • Uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic BP > 90 mm Hg despite optimal antihypertensive treatment
  • Tumors invading the GI-tract, active peptic ulcer disease, acute pancreatitis, acute obstruction of the pancreatic or biliary duct, appendicitis, cholangitis, cholecystitis, diverticulitis, gastric outlet obstruction, or inflammatory bowel disease
  • Abdominal fistula, bowel obstruction, GI perforation, or intra-abdominal abscess within 6 months before initiation of study treatment
  • Known cavitating pulmonary lesion(s) or known endobronchial disease manifestation
  • Lesions invading major pulmonary blood vessels
  • hematuria, hematemesis, hemoptysis of > 0.5 teaspoon (2.5 mL) of red blood, coagulopathy, or other history of significant bleeding within 3 months before initiation of study treatment
  • Serious non-healing wound/ulcer/bone fracture
  • Malabsorption syndrome
  • Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption are also excluded.
  • Requirement for hemodialysis or peritoneal dialysis
  • Inability to swallow tablets
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    Atezolizumab + Cabozantinib

    Participants received atezolizumab on Day 1 of each 21-day cycle and cabozantinib orally once daily on Days 1-21 of each cycle.

    Drug: Cabozantinib · Drug: Atezolizumab

  • Active comparator
    Docetaxel

    Participants received docetaxel on Day 1 of each 21-day cycle.

    Drug: Docetaxel

Interventions

  • Cabozantinib will be administered orally, once daily at a dose of 40 mg on Days 1-21 of each cycle.

  • Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.

    Also known as: Tecentriq

  • Docetaxel will be administered by IV infusion at a starting dose of 75mg/m2 on Day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death from any cause. Participants alive at the time of the analysis were censored at the date when they were last known to be alive as documented by the investigator. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. Progression-Free Survival (PFS) as Determined by Investigator

    PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1), or death from any cause (whichever occurred first). PD was defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters of the target lesions recorded since the treatment started, including screening, or the appearance of one or more new lesions. In addition, the sum of diameters also demonstrated an absolute increase of ≥ 5 millimeters (mm). Participants who were alive and did not experience PD at the time of analysis, were censored on the date of last tumor assessment. Participants with no post-baseline tumor assessment were censored at the date of randomization. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Up to approximately 24 months

  2. Confirmed Objective Response Rate (ORR) as Determined by Investigator

    Confirmed ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to RECIST v1.1. CR= disappearance of all target lesions. In addition, any pathological lymph nodes must have a reduction in short axis to \< 10 mm. PR= at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. 95% CIs for rates were constructed using the Clopper-Pearson method. Percentages have been rounded off.

    Time frame: Up to approximately 24 months

  3. Duration of Response (DOR) as Determined by Investigator

    DOR for participants with confirmed ORR=time from first documented objective response to PD, as determined by investigator per RECIST v1.1, or death from any cause (whichever occurred first). PD=≥ 20% increase in sum of longest diameters of target lesions, taking as reference smallest sum of longest diameters of target lesions recorded since treatment started, including screening, or appearance of new lesions. In addition, sum of diameters also demonstrated an absolute increase of ≥ 5 mm. Confirmed ORR=percentage of participants with a CR or PR on two consecutive occasions ≥4 weeks apart, as determined by investigator per RECIST v1.1. CR= disappearance of all target lesions. PR=≥ 30% decrease in sum of diameters of all target lesions. Participants who had not progressed and who did not die at the time of analysis were censored at the time of last tumor assessment date. Kaplan-Meier method was used to estimate median. 95% CI for median was computed using Brookmeyer and Crowley method.

    Time frame: Up to approximately 24 months

  4. Time to Confirmed Deterioration (TTCD) in Patient-reported Physical Functioning (PF)

    TTCD analyses was performed for patient-reported PF (items 1 to 5) of European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30). The PF was measured on 4-point scale (1='Not at all' to 4='Very much'). TTCD for PF was defined as time from date of randomization to first confirmed clinically meaningful decrease from baseline in PF score held for at least 2 consecutive assessments or initial clinically meaningful decrease from baseline followed by death from any cause within 21 days or until next tumor assessment, whichever occurs first. A score change of ≥ of 10-point on EORTC QLQ-C30 PF scale was determined as being clinically meaningful. Scores were averaged, transformed to 0-100 scale; where higher score represented high/healthy level of functioning. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Up to approximately 24 months

  5. TTCD in Patient-reported Global Health Status (GHS)

    TTCD analyses was performed for GHS and quality of life (QoL) (items 29 and 30) of EORTC QLQ-C30. GHS/ QoL items were scored on a 7-point scale that ranges from "very poor" to "excellent." TTCD for GHS/QoL was defined as the time from the date of randomization to the first confirmed clinically meaningful decrease from baseline in GHS/QoL score held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 21 days or until the next tumor assessment, whichever occurs first. A score change of ≥ 10-point on the EORTC QLQ-C30 GHS/QoL scale was determined as being clinically meaningful. Scores were averaged, transformed to 0-100 scale; where higher score for GHS/QoL= better health-related QoL. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Up to approximately 24 months

  6. PFS Rates Assessed by Investigator

    PFS rates were defined as the percentage of participants alive and without PD as assessed by the investigator according to RECIST v1.1 at 6 months and 1 year after randomization. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints, including baseline. In addition, the sum of diameters also demonstrated an absolute increase of ≥ 5 mm. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley. Percentages have been rounded off.

    Time frame: 6 months and 1 year

  7. OS Rates

    OS rates were defined as the percentage of participants who were alive at 1 and 2 years. Participants alive at the time of the analysis were censored at the date when they were last known to be alive as documented by the investigator. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley. Percentages have been rounded off.

    Time frame: 1 and 2 years

  8. Percentage of Participants With Adverse Events (AEs)

    An AE was defined as any untoward medical occurrence in a clinical investigation patient administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following: unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product; any new disease or exacerbation of an existing disease; recurrence of an intermittent medical condition not present at baseline; any deterioration in a laboratory value or other clinical test; AEs related to a protocol-mandated intervention. AEs were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE, v5.0). Percentages have been rounded off.

    Time frame: Up to approximately 41.4 months

  9. Minimum Serum Concentration (Cmin) of Atezolizumab

    Time frame: Predose on Day 1 of Cycles 1, 2, 3, 4, 8, 12 and 16 (Cycle= 21 days)

  10. Maximum Serum Concentration (Cmax) of Atezolizumab

    Time frame: 30 minutes (min) postdose on Day 1 of Cycle 1 (Cycle= 21 days)

  11. Minimum Plasma Concentration (Cmin) of Cabozantinib

    Time frame: Predose on Day 1 of Cycles 1, 2, 3, 4, and 5 (Cycle= 21 days)

  12. Maximum Plasma Concentration (Cmax) of Cabozantinib

    Time frame: Predose on Day 1 of Cycles 1, 2, 3, 4, and 5 (Cycle= 21 days)

  13. Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab

    Participants were considered to be ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (treatment-enhanced ADA response). The total number of participants who developed ADAs to atezolizumab was determined by summing the ADA-positive participants across all timepoints.

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 and post-treatment follow-up (≤ 30 days after final dose) (Cycle= 21 days)

07

Results

Posted Dec 20, 2023

Participant flow

A total of 366 participants with metastatic non-small cell lung cancer (NSCLC) previously treated with anti-programmed death ligand 1/programmed cell death protein 1 (PD-L1/PD-1) antibody and platinum-containing chemotherapy took part in the study at 97 investigative sites across 15 countries from 01 October 2020 to 17 January 2025.

Participant flow — Overall Study
MilestoneDocetaxel MonotherapyAtezolizumab + Cabozantinib
Started180186
Safety-evaluable population167185
Completed00
Not completed180186
Withdrew: Withdrawal by subject294
Withdrew: Physician decision01
Withdrew: Reason not specified02
Withdrew: Death131147
Withdrew: Lost to follow-up03
Withdrew: Study terminated by sponsor2029

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death from any cause. Participants alive at the time of the analysis were censored at the date when they were last known to be alive as documented by the investigator. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Up to approximately 24 months
Reported as:
Median · months
Overall Survival (OS)
monthsDocetaxel MonotherapyAtezolizumab + Cabozantinib
Overall Survival (OS)10.5 (8.6 to 13.0)10.7 (8.8 to 12.3)
Statistical analysis
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Log Rank · p = 0.3668 · Hazard ratio (hr): 0.884 · 95% CI 0.676 to 1.156Hazard ratio was estimated by Cox regression model.
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Log Rank · p = 0.4709 · Hazard ratio (hr): 0.907 · 95% CI 0.696 to 1.182Hazard ratio was estimated by Cox regression model.
SecondaryProgression-Free Survival (PFS) as Determined by Investigator

PFS was defined as the time from randomization to the first occurrence of PD, as determined by the investigator according to response evaluation criteria in solid tumors version 1.1 (RECIST v1.1), or death from any cause (whichever occurred first). PD was defined as at least a 20% increase in the sum of the longest diameters of target lesions, taking as reference the smallest sum of the longest diameters of the target lesions recorded since the treatment started, including screening, or the appearance of one or more new lesions. In addition, the sum of diameters also demonstrated an absolute increase of ≥ 5 millimeters (mm). Participants who were alive and did not experience PD at the time of analysis, were censored on the date of last tumor assessment. Participants with no post-baseline tumor assessment were censored at the date of randomization. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Up to approximately 24 months
Reported as:
Median · months
Progression-Free Survival (PFS) as Determined by Investigator
monthsDocetaxel MonotherapyAtezolizumab + Cabozantinib
Progression-Free Survival (PFS) as Determined by Investigator4.0 (3.1 to 4.4)4.6 (4.1 to 5.6)
Statistical analysis
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Log Rank · p = 0.0079 · Hazard ratio (hr): 0.735 · 95% CI 0.585 to 0.923Hazard ratio was estimated by Cox regression model.
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Log Rank · p = 0.0061 · Hazard ratio (hr): 0.731 · 95% CI 0.583 to 0.915Hazard ratio was estimated by Cox regression model.
SecondaryConfirmed Objective Response Rate (ORR) as Determined by Investigator

Confirmed ORR was defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to RECIST v1.1. CR= disappearance of all target lesions. In addition, any pathological lymph nodes must have a reduction in short axis to \< 10 mm. PR= at least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. 95% CIs for rates were constructed using the Clopper-Pearson method. Percentages have been rounded off.

Time frame:
Up to approximately 24 months
Reported as:
Number · percentage of participants
Confirmed Objective Response Rate (ORR) as Determined by Investigator
percentage of participantsDocetaxel MonotherapyAtezolizumab + Cabozantinib
Confirmed Objective Response Rate (ORR) as Determined by Investigator13.3 (8.73 to 19.19)11.8 (7.56 to 17.36)
Statistical analysis
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Cochran-Mantel-Haenszel · p = 0.6846 · Difference in response rates: -1.51 · 95% CI -8.85 to 5.8495% CIs was computed using the Wald method.
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Odds ratio (or): 0.88 · 95% CI 0.47 to 1.63Odds ratios were estimated by logistic regression. 95% CIs was computed using the Wald method.
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Chi-squared, Corrected · p = 0.7216 · Difference in response rates: -1.51 · 95% CI -8.85 to 5.8495% CIs was computed using the Wald method.
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Odds ratio (or): 0.87 · 95% CI 0.47 to 1.62Odds ratios were estimated by logistic regression. 95% CIs was computed using the Wald method.
SecondaryDuration of Response (DOR) as Determined by Investigator

DOR for participants with confirmed ORR=time from first documented objective response to PD, as determined by investigator per RECIST v1.1, or death from any cause (whichever occurred first). PD=≥ 20% increase in sum of longest diameters of target lesions, taking as reference smallest sum of longest diameters of target lesions recorded since treatment started, including screening, or appearance of new lesions. In addition, sum of diameters also demonstrated an absolute increase of ≥ 5 mm. Confirmed ORR=percentage of participants with a CR or PR on two consecutive occasions ≥4 weeks apart, as determined by investigator per RECIST v1.1. CR= disappearance of all target lesions. PR=≥ 30% decrease in sum of diameters of all target lesions. Participants who had not progressed and who did not die at the time of analysis were censored at the time of last tumor assessment date. Kaplan-Meier method was used to estimate median. 95% CI for median was computed using Brookmeyer and Crowley method.

Time frame:
Up to approximately 24 months
Reported as:
Median · months
Duration of Response (DOR) as Determined by Investigator
monthsDocetaxel MonotherapyAtezolizumab + Cabozantinib
Duration of Response (DOR) as Determined by Investigator4.30 (3.29 to 5.62)5.55 (3.12 to 10.25)
SecondaryTime to Confirmed Deterioration (TTCD) in Patient-reported Physical Functioning (PF)

TTCD analyses was performed for patient-reported PF (items 1 to 5) of European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30). The PF was measured on 4-point scale (1='Not at all' to 4='Very much'). TTCD for PF was defined as time from date of randomization to first confirmed clinically meaningful decrease from baseline in PF score held for at least 2 consecutive assessments or initial clinically meaningful decrease from baseline followed by death from any cause within 21 days or until next tumor assessment, whichever occurs first. A score change of ≥ of 10-point on EORTC QLQ-C30 PF scale was determined as being clinically meaningful. Scores were averaged, transformed to 0-100 scale; where higher score represented high/healthy level of functioning. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Up to approximately 24 months
Reported as:
Median · months
Time to Confirmed Deterioration (TTCD) in Patient-reported Physical Functioning (PF)
monthsDocetaxel MonotherapyAtezolizumab + Cabozantinib
Time to Confirmed Deterioration (TTCD) in Patient-reported Physical Functioning (PF)5.6 (4.0 to NA)7.7 (4.8 to 14.7)
Statistical analysis
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Log Rank · p = 0.2700 · Hazard ratio (hr): 0.82 · 95% CI 0.59 to 1.16Hazard ratio was estimated by Cox regression model.
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Log Rank · p = 0.3031 · Hazard ratio (hr): 0.84 · 95% CI 0.60 to 1.17Hazard ratio was estimated by Cox regression model.
SecondaryTTCD in Patient-reported Global Health Status (GHS)

TTCD analyses was performed for GHS and quality of life (QoL) (items 29 and 30) of EORTC QLQ-C30. GHS/ QoL items were scored on a 7-point scale that ranges from "very poor" to "excellent." TTCD for GHS/QoL was defined as the time from the date of randomization to the first confirmed clinically meaningful decrease from baseline in GHS/QoL score held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 21 days or until the next tumor assessment, whichever occurs first. A score change of ≥ 10-point on the EORTC QLQ-C30 GHS/QoL scale was determined as being clinically meaningful. Scores were averaged, transformed to 0-100 scale; where higher score for GHS/QoL= better health-related QoL. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Up to approximately 24 months
Reported as:
Median · months
TTCD in Patient-reported Global Health Status (GHS)
monthsDocetaxel MonotherapyAtezolizumab + Cabozantinib
TTCD in Patient-reported Global Health Status (GHS)14.1 (6.3 to NA)8.1 (5.6 to 14.5)
Statistical analysis
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Log Rank · p = 0.2408 · Hazard ratio (hr): 1.24 · 95% CI 0.86 to 1.79Hazard ratio was estimated by Cox regression model.
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · Log Rank · p = 0.1992 · Hazard ratio (hr): 1.26 · 95% CI 0.88 to 1.81Hazard ratio was estimated by Cox regression model.
SecondaryPFS Rates Assessed by Investigator

PFS rates were defined as the percentage of participants alive and without PD as assessed by the investigator according to RECIST v1.1 at 6 months and 1 year after randomization. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters at prior timepoints, including baseline. In addition, the sum of diameters also demonstrated an absolute increase of ≥ 5 mm. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley. Percentages have been rounded off.

Time frame:
6 months and 1 year
Reported as:
Number · percentage of participants
PFS Rates Assessed by Investigator
percentage of participantsDocetaxel MonotherapyAtezolizumab + Cabozantinib
At 6 months23.66 (16.98 to 30.33)39.51 (32.42 to 46.59)
At 1 year8.38 (3.95 to 12.80)14.70 (9.43 to 19.97)
Statistical analysis
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · z-test · p = 0.0014 · Difference in event free rate: 15.85 · 95% CI 6.12 to 25.59The 95% CI for the difference in PFS rates were estimated using the normal approximation method, with standard errors computed using the Greenwood method.
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · z-test · p = 0.0719 · Difference in event free rate: 6.32 · 95% CI -0.56 to 13.21The 95% CI for the difference in PFS rates were estimated using the normal approximation method, with standard errors computed using the Greenwood method.
SecondaryOS Rates

OS rates were defined as the percentage of participants who were alive at 1 and 2 years. Participants alive at the time of the analysis were censored at the date when they were last known to be alive as documented by the investigator. Kaplan-Meier method was used to estimate the median. 95% CI for median was computed using the method of Brookmeyer and Crowley. Percentages have been rounded off.

Time frame:
1 and 2 years
Reported as:
Number · percentage of participants
OS Rates
percentage of participantsDocetaxel MonotherapyAtezolizumab + Cabozantinib
1 year44.12 (36.20 to 52.05)43.27 (35.97 to 50.57)
2 yearsNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Docetaxel Monotherapy vs Atezolizumab + Cabozantinib · z-test · p = 0.8767 · Difference in event free rate: -0.85 · 95% CI -11.63 to 9.92The 95% CI for the difference in OS rates were estimated using the normal approximation method, with standard errors computed using the Greenwood method.
SecondaryPercentage of Participants With Adverse Events (AEs)

An AE was defined as any untoward medical occurrence in a clinical investigation patient administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any of the following: unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product; any new disease or exacerbation of an existing disease; recurrence of an intermittent medical condition not present at baseline; any deterioration in a laboratory value or other clinical test; AEs related to a protocol-mandated intervention. AEs were assessed using National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE, v5.0). Percentages have been rounded off.

Time frame:
Up to approximately 41.4 months
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsDocetaxel MonotherapyAtezolizumab + Cabozantinib
Percentage of Participants With Adverse Events (AEs)94.098.4
SecondaryMinimum Serum Concentration (Cmin) of Atezolizumab
Time frame:
Predose on Day 1 of Cycles 1, 2, 3, 4, 8, 12 and 16 (Cycle= 21 days)
Reported as:
Geometric mean · microgram/milliliter (μg/ml)
Minimum Serum Concentration (Cmin) of Atezolizumab
microgram/milliliter (μg/ml)Atezolizumab + Cabozantinib
Cycle 1 Day 1NA ± NA
Cycle 2 Day 196.8 ± 48.1
Cycle 3 Day 1124 ± 104.4
Cycle 4 Day 1167 ± 47.7
Cycle 8 Day 1194 ± 62.4
Cycle 12 Day 1233 ± 44.7
Cycle 16 Day 1209 ± 56.1
SecondaryMaximum Serum Concentration (Cmax) of Atezolizumab
Time frame:
30 minutes (min) postdose on Day 1 of Cycle 1 (Cycle= 21 days)
Reported as:
Geometric mean · μg/mL
Maximum Serum Concentration (Cmax) of Atezolizumab
μg/mLAtezolizumab + Cabozantinib
Maximum Serum Concentration (Cmax) of Atezolizumab450 ± 34.0
SecondaryMinimum Plasma Concentration (Cmin) of Cabozantinib
Time frame:
Predose on Day 1 of Cycles 1, 2, 3, 4, and 5 (Cycle= 21 days)
Reported as:
Geometric mean · μg/mL
Minimum Plasma Concentration (Cmin) of Cabozantinib
μg/mLAtezolizumab + Cabozantinib
Cycle 1 Day 1NA ± NA
Cycle 2 Day 10.746 ± 111.7
Cycle 3 Day 10.418 ± 640.7
Cycle 4 Day 10.469 ± 234.4
Cycle 5 Day 10.303 ± 402.3
SecondaryMaximum Plasma Concentration (Cmax) of Cabozantinib
Time frame:
Predose on Day 1 of Cycles 1, 2, 3, 4, and 5 (Cycle= 21 days)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab

Participants were considered to be ADA positive if they were ADA negative or had missing data at baseline but developed an ADA response following study drug exposure (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer unit greater than the titer of the baseline sample (treatment-enhanced ADA response). The total number of participants who developed ADAs to atezolizumab was determined by summing the ADA-positive participants across all timepoints.

Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8, 12, 16 and post-treatment follow-up (≤ 30 days after final dose) (Cycle= 21 days)
Reported as:
Count of participants · Participants
Number of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab
ParticipantsAtezolizumab + Cabozantinib
ADA Prevalence at Baseline2
ADA Incidence after treatment37

Adverse events

Collected over All-cause mortality: Up to 44.6 months SAE and other AEs: Up to 41.4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel Monotherapy131/180 (72.8%)58/167 (34.7%)148/167 (88.6%)
Atezolizumab + Cabozantinib147/186 (79%)76/185 (41.1%)173/185 (93.5%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventDocetaxel MonotherapyAtezolizumab + Cabozantinib
PneumoniaInfections and infestations10/16710/185
Febrile neutropeniaBlood and lymphatic system disorders8/1670/185
PneumonitisRespiratory, thoracic and mediastinal disorders5/1673/185
PyrexiaGeneral disorders1/1675/185
Respiratory failureRespiratory, thoracic and mediastinal disorders4/1670/185
DiarrhoeaGastrointestinal disorders3/1674/185
Vascular device infectionInfections and infestations0/1674/185
NeutropeniaBlood and lymphatic system disorders3/1671/185
DyspnoeaRespiratory, thoracic and mediastinal disorders3/1672/185
VomitingGastrointestinal disorders0/1673/185
Most frequent other events
Showing 10 of 50
Most frequent other events
EventDocetaxel MonotherapyAtezolizumab + Cabozantinib
DiarrhoeaGastrointestinal disorders38/16783/185
Decreased appetiteMetabolism and nutrition disorders28/16759/185
FatigueGeneral disorders44/16742/185
NauseaGastrointestinal disorders29/16747/185
AstheniaGeneral disorders40/16743/185
AlopeciaSkin and subcutaneous tissue disorders40/1674/185
AnaemiaBlood and lymphatic system disorders38/16724/185
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders2/16740/185
Alanine aminotransferase increasedInvestigations7/16736/185
ConstipationGastrointestinal disorders17/16731/185

Baseline characteristics

The Intent-to-treat (ITT) population included all randomized participants, whether or not the participant received the assigned treatment.

Age, Continuous
Age, Continuous(years)Docetaxel MonotherapyAtezolizumab + CabozantinibTotal
Mean64.4 ± 9.463.8 ± 9.564.1 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel MonotherapyAtezolizumab + CabozantinibTotal
Female5352105
Male127134261
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Docetaxel MonotherapyAtezolizumab + CabozantinibTotal
American Indian or Alaska Native000
Asian534194
Native Hawaiian or Other Pacific Islander000
Black or African American123
White111130241
More than one race000
Unknown or Not Reported151328
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Docetaxel MonotherapyAtezolizumab + CabozantinibTotal
Hispanic or Latino7411
Not Hispanic or Latino158164322
Not Stated121527
Unknown336
08

Study locations

92 sites
  • Stanford University
    Palo Alto, California 94305, United States
  • Kaiser Permanente - San Diego
    San Diego, California 92120, United States
  • Sansum Clinic
    Santa Barbara, California 93105, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80220, United States
  • Regional Cancer Care Associates
    Bethesda, Maryland 20817, United States
  • Minnesota Oncology Hematology
    Saint Paul, Minnesota 55102, United States
  • Consultants in Medical Oncology and Hematology
    Broomall, Pennsylvania 19008, United States
  • Charleston Oncology, P .A
    Charleston, South Carolina 29414, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Huntsman Cancer Institute at The University of Utah
    Salt Lake City, Utah 84112, United States
  • Oncology and Hematology Associates of Southwest Virginia, Inc.,-Blacksburg
    Blacksburg, Virginia 24060, United States
  • Virginia Cancer Specialists (Fairfax) - USOR
    Fairfax, Virginia 22031, United States
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Townsville Hospital
    Townsville, Queensland 4810, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Austin Hospital Olivia Newton John Cancer Centre
    Heidelberg, Victoria 3084, Australia
  • Affinity Oncology
    Nedlands, Western Australia 6009, Australia
  • Lkh-Univ. Klinikum Graz
    Graz, 8036, Austria
  • Ordensklinikum Linz Elisabethinen
    Linz, 4020, Austria
  • Lhk Feldkirch
    Rankweil, 6830, Austria
  • Lkh Salzburg - Univ. Klinikum Salzburg
    Salzburg, 5020, Austria
  • Medizinische Universität Wien
    Vienna, 1090, Austria
  • Institut Jules Bordet
    Anderlecht, 1070, Belgium
  • Cliniques Universitaires St-Luc
    Brussels, 1200, Belgium
  • Clinique Ste-Elisabeth
    Namur, 5000, Belgium
  • CHU Angers,Service de Pneumologie
    Angers, 49933, France
  • CHU de Grenoble
    Grenoble, 38043, France
  • Hopital Dupuytren
    Limoges, 87042, France
  • Hôpital Saint Joseph
    Marseille, 13285, France
  • Centre Regional de Lutte contre le Cancer Val d Aurelle - Paul Lamarque
    Montpellier, 34298, France
  • Hopital Tenon
    Paris, 75970, France
  • Zentralklinik Bad Berka GmbH
    Bad Berka, 99437, Germany
  • Klinikum Koeln-Merheim
    Cologne, 51109, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH
    Giessen, 35392, Germany
  • KRH Klinikum Siloah-Oststadt-Heidehaus
    Hanover, 30459, Germany
  • Universitaetsklinikum Giessen und Marburg
    Marburg, 35043, Germany
  • Brüderkrankenhaus St. Josef Paderborn
    Paderborn, 33098, Germany
  • Uoa Sotiria Hospital
    Athens, 115 27, Greece
  • Henri Dunant Hospital
    Athens, 11526, Greece
  • Univ General Hosp Heraklion
    Heraklion, 711 10, Greece
  • Euromedical General Clinic of Thessaloniki
    Thessaloniki, 546 45, Greece
  • Ospedale Vito Fazzi
    Lecce, Apulia 73100, Italy
  • AORN Ospedali dei Colli Ospedale Monaldi
    Naples, Campania 80131, Italy
  • Azienda Ospedaliero Universitaria di Parma
    Parma, Emilia-Romagna 43100, Italy
  • Ospedale Provinciale Santa Maria Delle Croci
    Ravenna, Emilia-Romagna 48100, Italy
  • Irccs Centro Di Riferimento Oncologico (CRO)
    Aviano, Friuli Venezia Giulia 33081, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Rome, Lazio 00151, Italy
  • Policlinico Umberto I, Oncologia B
    Rome, Lazio 00161, Italy
  • IRCCS AOU San Martino - IST
    Genoa, Liguria 16132, Italy
  • ASST Spedali Civili di Brescia
    Brescia, Lombardy 25123, Italy
  • Instituto Europeo di Oncologia
    Milan, Lombardy 20141, Italy
  • A.O.U Careggi
    Florence, Tuscany 50124, Italy
  • Hyogo Cancer Center
    Hyōgo, 673-0021, Japan
  • Sendai Kousei Hospital
    Miyagi, 981-0914, Japan
  • Osaka International Cancer Institute
    Osaka, 541-8567, Japan
  • National Cancer Center Hospital
    Tokyo, 104-0045, Japan
  • The Cancer Institute Hospital of JFCR
    Tokyo, 135-8550, Japan
  • Centrum Onkologii im. Prof. Franciszka ?ukaszczyka
    Bydgoszcz, 85-796, Poland
  • SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4
    Bytom, 41-902, Poland
  • Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice
    Gliwice, 44-101, Poland
  • Szpital Wojewódzki im. Miko?aja Kopernika
    Koszalin, 75-581, Poland
  • Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy
    Otwock, 05-400, Poland
  • Centro Hospitalar do Porto ? Hospital de Santo António
    Porto, 4099-001, Portugal
  • Hospital CUF Porto
    Porto, 4100-180, Portugal
  • IPO do Porto
    Porto, 4200-072, Portugal
  • CHVNG/E_Unidade 1
    Vila Nova de Gaia, 4434-502, Portugal
  • MEDSI Clinical Hospital on Pyatnitsky Highway
    Moscow, Moscow Oblast 143422, Russia
  • GBUZ Leningradskaya state clinical hospital
    Saint Petersburg, Sankt-Peterburg 194291, Russia
  • S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)
    Saint Petersburg, Sankt-Peterburg 197758, Russia
  • Regional Clinical Oncology Hospital
    Yaroslavl, Yaroslavl Oblast 150054, Russia
  • Chungbuk National University Hospital
    Cheongju-si, 28644, South Korea
  • National Cancer Center
    Goyang-si, 10408, South Korea
  • St. Vincent's Hospital
    Gyeonggi-do, 16247, South Korea
  • Ajou University Medical Center
    Gyeonggi-do, 16499, South Korea
  • Samsung Changwon Hospital
    Gyeongsangnam-do, 51353, South Korea
  • Gachon University Gil Medical Center
    Incheon, 21565, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, 13605, South Korea
  • Korea University Anam Hospital
    Seoul, 02841, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Seoul St Mary's Hospital
    Seoul, 06591, South Korea
  • Ulsan University Hosiptal
    Ulsan, 44033, South Korea
  • Complejo Hospitalario Universitario A Coruña (CHUAC)
    A Coruña, 15006, Spain
  • Institut Catala d Oncologia Hospital Duran i Reynals
    L'Hospitalet de LLobegat, 08908, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Univ. Nuestra Señora de Valme
    Seville, 41014, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • Addenbrookes Hospital
    Cambridge, CB2 0QQ, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 OYN, United Kingdom
  • Barts & London School of Med
    London, EC1A 7BE, United Kingdom
  • University College London Hospital
    London, NW1 - 2PG, United Kingdom
  • Chelsea & Westminster Hospital
    London, SW10 9NH, United Kingdom
09

References and documents

Publications

  • Neal J, Pavlakis N, Kim SW, Goto Y, Lim SM, Mountzios G, Fountzilas E, Mochalova A, Christoph DC, Bearz A, Quantin X, Palmero R, Antic V, Chun E, Edubilli TR, Lin YC, Huseni M, Ballinger M, Graupner V, Curran D, Vervaet P, Newsom-Davis T. CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy. J Clin Oncol. 2024 Jul 10;42(20):2393-2403. doi: 10.1200/JCO.23.02166. Epub 2024 Mar 29. PubMed 38552197 ↗
  • Xing P, Wang M, Zhao J, Zhong W, Chi Y, Xu Z, Li J. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. Thorac Cancer. 2021 Oct;12(20):2825-2828. doi: 10.1111/1759-7714.14113. Epub 2021 Aug 18. PubMed 34409776 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Sep 2022, 23 months.

Results were first posted in Dec 2023, 1 year 2 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 23 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2020
First posted
Jul 15, 2020
StartActual
Oct 1, 2020
Primary completionActual
Sep 28, 2022
CompletionActual
Jan 17, 2025
Results first posted
Dec 20, 2023
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04471428
Lead sponsor
Hoffmann-La Roche
Collaborators
Exelixis
Responsible party
Sponsor
First posted
Jul 15, 2020
Start date
Oct 1, 2020
Primary completion
Sep 28, 2022
Completion
Jan 17, 2025
Results posted
Dec 20, 2023
Last update
Dec 22, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabozantinib · Atezolizumab · Docetaxel

Start the discussion